Compare ITGR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | LIVN |
|---|---|---|
| Founded | 1970 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2000 | 2015 |
| Metric | ITGR | LIVN |
|---|---|---|
| Price | $86.41 | $65.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $91.14 | $70.25 |
| AVG Volume (30 Days) | ★ 954.6K | 811.9K |
| Earning Date | 05-18-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | $1.37 | $8.14 |
| Revenue Next Year | $8.25 | $6.53 |
| P/E Ratio | $30.03 | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $32.48 |
| 52 Week High | $127.56 | $71.58 |
| Indicator | ITGR | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 46.86 |
| Support Level | $83.08 | $61.80 |
| Resistance Level | $87.54 | $67.92 |
| Average True Range (ATR) | 3.67 | 2.44 |
| MACD | -0.14 | -0.17 |
| Stochastic Oscillator | 21.11 | 38.64 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.